Tier 2 — strong

Quercetin and polycystic ovary syndrome; inflammation, hormonal parameters and pregnancy outcome: A randomized clinical trial

Sima Vaez, Kazem Parivr, Fardin Amidi, Nasim Hayati Rudbari, Ashraf Moini, Naser Amini
American journal of reproductive immunology (New York, N.Y. : 1989) 2023 89(3):e13644

Bibliography

PubMed
PMID 36317442
DOI
10.1111/aji.13644
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized placebo-controlled PCOS trial
ModelHuman intervention research
Sample72 women with polycystic ovary syndrome
InterventionQuercetin 500 mg/day versus placebo
DurationAbstract describes 40 days but also refers to a 3-month assessment
EndpointsInflammatory measures

What the study showed, in plain terms

Published in 2023, this source examined hormones and reproductive health. Design: Randomized placebo-controlled PCOS trial. Sample/model: 72 women with polycystic ovary syndrome. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: Abstract describes 40 days but also refers to a 3-month assessment.

Selected LH, FSH and IL-6 changes favored quercetin; the authors also reported favorable reproductive outcomes.

The abstract contains inconsistent timing and incomplete between-group reproductive data. Fertility-effect magnitude requires the complete report.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected LH, FSH and IL-6 changes favored quercetin; the authors also reported favorable reproductive outcomes.
  • The recorded outcome domains were Inflammatory measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; Abstract describes 40 days but also refers to a 3-month assessment.

What this study can and cannot tell us

  • The abstract contains inconsistent timing and incomplete between-group reproductive data. Fertility-effect magnitude requires the complete report.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Oral Quercetin Supplementation Enhances Adiponectin Receptor Transcript Expression in Polycystic Ovary Syndrome Patients: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Neda Rezvan et al. · Cell journal · 2018
Tier 2
The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome
Masoud Khorshidi et al. · Phytotherapy research : PTR · 2018
Tier 2
Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial
N Rezvan et al. · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology